Bioresorbable Scaffolds Carry Higher Ischemic Risk Than Drug-Eluting Stents Through Five Years
This 51-study meta-analysis with trial sequential analysis quantifies the thrombosis, myocardial infarction, and revascularization penalty of bioresorbable scaffolds relative to contemporary drug-eluting stents, giving cardiology pharmacists a consolidated basis for antiplatelet and device-selection discussions.
📅 Journal publication: Oct 2026(online Oct 20, 2026)·Last updated: Nov 5, 2026
Drug-eluting stents outperform bioresorbable scaffolds in coronary artery safety.
Understanding the comparative efficacy of bioresorbable vascular scaffolds (BVS) versus drug-eluting stents (DES) is crucial for improving outcomes in coronary artery disease. BVS showed a higher risk of adverse events at one year, including myocardial infarction (MI) and thrombosis, compared to DES. The evidence suggests BVS presents higher ischemic risks with no long-term survival benefit, indicating DES should remain the standard revascularization strategy. DES outperforms BVS in safety and efficacy for coronary artery disease revascularization.
📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.
Free account, no credit card. Includes 1 full deep analysis every month.
Authors:Yu Y, Shang K, Jiao Y, Chang S, Li Y, Song G, Yin C
Citation:Yu Y, Shang K, Jiao Y, et al. Efficacy and Safety of Bioresorbable Vascular Scaffolds Versus Contemporary Drug-Eluting Stents in Coronary Artery Disease: A Systematic Review, Meta-Analysis, and Trial Sequential Analysis. Reviews in cardiovascular medicine. 2026;27(10):51636. doi:10.31083/RCM51636